Navigation Links
Crystalens HD(TM) Receives FDA Approval
Date:6/30/2008

Newest Version of the Only FDA Approved Accommodating Lens Designed to

Further Improve Near Vision

ALISO VIEJO, Calif., June 30 /PRNewswire/ -- Bausch & Lomb announced today that it has received approval from the Food and Drug Administration (FDA) to market the Crystalens HD(TM) in the United States. Crystalens accommodating intraocular lens (IOL) was first approved by the FDA in November 2003. The Crystalens HD is the fourth generation of the only FDA approved accommodating lens.

The surface of the Crystalens HD has been shaped to enhance the depth of focus with a proprietary optical modification. The enhanced optic provides an increased depth of focus which is designed to improve near vision without compromising intermediate or distance vision. The HD lens does this without inducing increased undesirable dysphotopsia or night vision symptoms.

A total of 125 primary eyes were implanted with the Crystalens HD in patients who had a visually significant cataract, less than 1 diopter of corneal astigmatism, and the potential for best corrected visual acuity (BCVA) of 20/25 or better in both eyes. Of these patients, 80% reported vision at J2 or better at four (4) months.

"Extensive market research has clearly indicated that patients and surgeons alike are asking for a truly accommodating IOL as their choice of lens. With these results, where patients reported getting one more line of near vision, we are coming ever closer to meeting the desired need for an optic that does provide truly good near vision without compromising the quality of vision at intermediate or distance," said Michael Judy, Chief Marketing Officer at Bausch & Lomb Surgical.

Dr. John Hovanesian was a Principal Investigator in the FDA study. Dr. Hovanesian serves as Clinical Instructor at the Jules Stein Eye Institute, UCLA in California and is in private practice at Harvard Eye Associates in Laguna Hills, California.

"If I were a patient having cataract surgery, I would want an IOL that projects a single point of focus and also provides a broad range of distance, intermediate and near vision. The Crystalens HD is the best available lens to achieve that goal," said Dr. Hovanesian. "There is no question that the HD will be my lens of choice for presbyopia correction in patients with cataracts."

Bausch & Lomb officials said that surgeons will be instructed to continue to use the same surgical protocols for the Crystalens HD as they have used in the past. The Company has said that it will begin shipping the Crystalens HD the week of July 7th.

ABOUT CRYSTALENS HD

Crystalens HD is a product developed by Bausch & Lomb. To learn more about Crystalens HD, please visit http://www.crystalens.com. The Crystalens(R) Call Center is 1-888-393-6642.

ABOUT BAUSCH & LOMB

Bausch & Lomb is an eye health company dedicated to perfecting vision and enhancing life. Bausch & Lomb offers the world's most comprehensive portfolio of eye health products. The Company has one of the oldest, best known and most respected healthcare brands in the world. Bausch & Lomb offers a full suite of products in cataract and vitreoretinal surgery including intraocular lenses and delivery systems, phacomulsification equipment and other surgical instruments and devices. To learn more about Bausch & Lomb, visit http://www.bausch.com


'/>"/>
SOURCE Bausch & Lomb
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GSW Worldwide Named Agency of Record for BioBehavioral Diagnostics Companys MMAT/ADHD(TM) System
2. Weight Watchers Receives Adverse U.K. VAT Ruling
3. Instrumentation Laboratory Receives Performance Award from Premier for Second Consecutive Year
4. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
5. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
6. Preshaw receives Young Investigator Award
7. Childers receives research in Oral Biology Award
8. Melvin receives Salivary Research Award
9. Fischman receives Pharmacology/Therapeutics/Toxicology Research Award
10. Atchison receives Behavioral, Epidemiological and Health Services Research Award
11. Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Calif. (PRWEB) , ... March 01, 2017 , ... Award-winning ... has completed 25 medical mission trips in underdeveloped nations, averaging more than one trip ... 2016. An article on the website features the details of his charitable ...
(Date:3/1/2017)... ... March 01, 2017 , ... NYC based Integrated practice Living Well ... to announce the addition of Orthopaedic Surgeon Dr. Donald E. Heitman. Dr. ... Cornell University with a Bachelor of Science degree in biology. He then obtained his ...
(Date:3/1/2017)... ... 01, 2017 , ... “There is Comfort for the Soul”: a loving account ... their all-too-brief time together, and the soul-healing comfort provided by God’s presence in the ... published author, Jerie A. Tau, a dog-loving medical professional whose work takes her to ...
(Date:3/1/2017)... ... ... Way: Key To One Flesh”: a collection of real marital scenarios and solutions for ... Cecilia Chiam, a writer who emigrated to the United States in 1978. , ... problems with the guidance and support of Holy Scripture. , “This is a ...
(Date:3/1/2017)... ... March 01, 2017 , ... Adherence Compliance, the ... Cannabis Compliance Program for Regulatory Agencies. The regulatory agency program is the first ... internal or outsourced compliance program options, as well as an app for inspections ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Sun Chlorella Corp ., the California -based ... Non-GMO Project Verification and the launch of individual serving packets ... for the Natural Products Expo West trade show, March 10-12 ... Chlorella Corp. has announced the Non-GMO Project Verification logo is ... Sun Chlorella tablets, 250mg and 500mg (20/100-day supplies) ...
(Date:3/1/2017)... March 1, 2017  Integrated Modular Design ... design and implementation of pre-fabricated healthcare products ... room headwalls, seeks to lead the construction ... solutions. Fueled by their leading-edge ... of reducing construction timelines and project risk, ...
(Date:3/1/2017)... , March 1, 2017  Global biotherapeutics leader ... the largest ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, ... T reatment with H izentra ® ).  ... the efficacy, safety and tolerability of two different doses ... (Immune Globulin Subcutaneous [Human]), compared with placebo, in the ...
Breaking Medicine Technology: